History of Ketamine Discovery
Ketamine was synthesized in 1962 by Calvin Stevens at Parke-Davis pharmaceutical laboratory as a derivative of phencyclidine (PCP), specifically designed to be a less hallucinogenic and shorter-acting anesthetic agent. 1, 2
Timeline of Development
Initial Synthesis and Early Testing (1962-1970)
- 1962: Calvin Stevens synthesized ketamine from phencyclidine, a molecule known for its psychodysleptic, hallucinogenic, and dissociative properties 1
- 1964: First human administration occurred at Jackson Prison in Michigan, USA, where its dissociative effects combined with short-duration anesthesia were documented 1
- 1966: A patent for human use was filed 1
- 1970: Ketamine received initial FDA approval and was introduced into clinical practice 3, 4
The drug was specifically developed to replace phencyclidine, which had unacceptable psychotomimetic side effects. The goal was to create an anesthetic with a better safety profile while maintaining the beneficial properties of dissociative anesthesia 2, 5.
Clinical Adoption Era (1970s-1980s)
During this period, ketamine was extensively studied in over 12,000 operative and diagnostic procedures involving more than 10,000 patients across 105 separate studies 3. It was used as:
- A sole general anesthetic agent
- An induction agent prior to other general anesthetics
- A supplement to other anesthetic agents
A pivotal discovery occurred in 1983 when ketamine's mechanism as an NMDA receptor antagonist was identified, fundamentally changing the understanding of its pharmacology and psychotomimetic effects 5.
Decline and Resurgence (1990s-Present)
As newer volatile and intravenous anesthetic agents with favorable side effect profiles emerged, ketamine use markedly decreased 2. However, the 1990s brought renewed interest through two parallel developments:
Clinical renaissance: The discovery of opioid-induced hyperalgesia sparked interest in ketamine's analgesic and anti-hyperalgesic properties, leading to reconsideration of low-dose ketamine in clinical practice 1, 2
Recreational abuse emergence: The first cases of ketamine abuse were reported in 1992 in France, leading to special surveillance and its inclusion in the list of narcotic drugs in 1997 1. By the late 1990s, it circulated in London nightclubs, and in 1999, the DEA added it to Schedule III of controlled substances 6.
Modern Applications (2000s-Present)
Recent decades have seen ketamine's therapeutic applications expand dramatically beyond anesthesia:
- Depression treatment: Discovery of rapid-acting antidepressant effects at sub-anesthetic doses via NMDA receptor antagonism, resulting in glutamate release and brain-derived neurotrophic factor stimulation 7, 8
- Additional therapeutic effects: Analgesia, anti-shock properties in hemorrhagic and septic conditions, anti-inflammatory effects, neuroprotection, and bronchodilation 2
- Esketamine development: The S-enantiomer has been specifically developed for treatment-resistant depression and received landmark FDA approval 8
Key Pharmacological Characteristics Identified
The historical development revealed ketamine's unique profile:
- Rapid onset (1 minute IV) with short duration (10-15 minutes) 9
- Preservation of airway and cardiovascular reflexes, unlike other sedatives 10
- Dissociative anesthetic properties producing a "trance-like cataleptic state" 9
- Dual analgesic and sedative properties, distinguishing it from other anesthetic agents 10
Common Pitfall in Historical Context
A critical limitation that persisted throughout ketamine's history is the emergence reaction—floating sensations, vivid dreams, hallucinations, and delirium occurring in 10-30% of adults 10, 9. This adverse effect significantly limited its adoption despite beneficial properties, though combining ketamine with midazolam was found to minimize this reaction 10, 9.